Pino FPE, Moya RKS, Ramos VWY, Guevara AAL

Idioma: Español
Referencias bibliográficas: 40
Paginas:
Archivo PDF: 411.12 Kb.

RESUMEN

La artritis reumatoide es una enfermedad autoinmune, sistémica, crónica, que afecta con más frecuencia a mujeres que a hombres, y se observa predominantemente en ancianos. El propósito de este trabajo es presentar el resultado de una revisión bibliográfica sobre aspectos generales relacionados con la patogenia de la artritis reumatoide y el manejo terapéutico actual, así como perspectivas futuras de nuevos enfoques terapéuticos. Existen dos subtipos principales de artritis reumatoide según la presencia o ausencia de anticuerpos antiproteína citrulinada. La citrulinación es catalizada por la enzima peptidilarginina-deiminasa dependiente de calcio, que cambia una arginina cargada positivamente a una citrulina polar, pero neutra como resultado de una modificación postraduccional. Este estudio se enfoca en el subconjunto de artritis reumatoide positivo para anticuerpos antiproteína citrulinada y se divide la progresión del proceso de artritis reumatoide en varias etapas. Cabe mencionar que estas etapas pueden ocurrir de forma secuencial o simultánea. Se requiere con urgencia una mejor comprensión de cómo los mecanismos patológicos impulsan el deterioro del progreso de la artritis reumatoide en los individuos con el fin de desarrollar terapias que tratarán eficazmente a los pacientes en cada etapa del progreso de la enfermedad.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(Suppl. 3):S265-S272.

2. Cho SK. Factors associated with time to diagnosis from symptom onset in patients with early rheumatoid arthritis. Korean J Intern Med. 2017;113.

3. Raza K. Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis. 2018;70:1822-5.

4. Ometto F. Methods used to assess remission and low disease activity in rheumatoid arthritis. Autoimmun Rev. 2017;9:161-4.

5. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis. 2001;60:214-7.

6. Bizzaro N. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther. 2013;15:R16.

7. Padyukov L. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis. 2011;70:259-65.

8. Seegobin SD. ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial. Arthritis Res Ther. 2014;16:R13.

9. Raychaudhuri S. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet. 2012;44:291-6.

10. Okada Y. Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations. Hum Mol Genet. 2014;23:6916-26.

11. Nabi G. Meta-analysis reveals PTPN22 1858C/T polymorphism confers susceptibility to rheumatoid arthritis in Caucasian but not in Asian population. Autoimmunity. 2016;49:197-210.

12. Goh LL. NLRP1, PTPN22 and PADI4 gene polymorphisms and rheumatoid arthritis in ACPA-positive Singaporean Chinese. Rheumatol Int. 2017;37:1295-1302.

13. McCarthy C. Brief report: genetic variation of the alpha1 (antitrypsin gene is associated with increased autoantibody production in rheumatoid arthritis. Arthritis Rheumatol. 2017;69:1576-79.

14. Castaneda-Delgado JE. Type I interferon gene response is increased in early and established rheumatoid arthritis and correlates with autoantibody production. Front Immunol. 2017;8:285.

15. Kuo CF. Familial aggregation of rheumatoid arthritis and co-aggregation of autoimmune diseases in affected families: a nationwide population-based study. Rheumatology. 2017;56:928-33.

16. van der Woude D. Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nat Genet. 2016;42:814-6.

17. Klareskog L. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54:38-46.

18. Meng W. DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis. Arthritis Res Ther. 2017;19:71.

19. Wu X. Molecular insight into gut microbiota and rheumatoid arthritis. Int J Mol Sci. 2016;17:431.

20. Chen J. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Med. 2016;8:43.

21. Gan RW. The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population. Rheumatology. 2017;56:2229-36.

22. Hu Y. Long-term dietary quality and risk of developing rheumatoid arthritis in women. Ann Rheum Dis. 2017;76:1357-64.

23. Pianta A. Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints. J Clin Invest. 2017;127:2946-56.

24. Edwards JC. The nature and origins of synovium: experimental approaches to the study of synoviocyte differentiation. J Anat. 1994;184(Pt 3):493-501.

25. Sergijenko A, Roelofs AJ, Riemen AH, De Bari C. Bone marrow contribution to synovial hyperplasia following joint surface injury. Arthritis Res Ther. 2016;18:166.

26. Sabeh F, Fox D, Weiss SJ. Membrane-type I matrix metalloproteinase dependent regulation of rheumatoid arthritis synoviocyte function. J Immunol. 2010;184:6396-6406.

27. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;65:2205-19.

28. Pap T, Korb-Pap A. Cartilage damage in osteoarthritis and rheumatoid arthritis (two unequal siblings. Nat Rev Rheumatol. 2015;11:606-15.

29. Arts EE, Fransen J, Den Broeder AA, van Riel P, Popa CD. Low disease activity (DAS28

30. Myasoedova E. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010;69:1310-14.

31. Chen YJ, Chang YT, Wang CB, Wu CY. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum. 2011;63:352-8.

32. Deane KD. Can rheumatoid arthritis be prevented? Best Pract. Res Clin Rheumatol. 2013;27:467-85.

33. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a metaanalysis. Arthritis Rheum. 2006;55:864-72.

34. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16:585-91.

35. Naldini L. Gene therapy returns to centre stage. Nature. 2015;526:351-60.

36. Kim MJ. Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy. J Control Release. 2015;216:140-48.

37. Lee SJ. TNF-alpha gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis. Mol Ther. 2014;22:397-408.

38. Lundstrom SL. IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis. Arthritis Res Ther. 2017;19:182.

39. Whang JA, Chang BY. Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Drug Discov Today. 2014;19:1200-04.

40. Alvaro-Gracia JM. Intravenous administration of expanded allogeneic adipose- derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis. 2017;76:196-202.